Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A cost comparison of a basal-bolus regimen (glargine and glulisine) with a premixed insulin regimen in type 2 diabetes patients: the GINGER study.

Autor: Vora, Jiten P, Punekar, Yogesh S, Keech, Martin L

Publikováno v: British Journal of Diabetes & Vascular Disease; Nov2011, Vol. 11 Issue 6, p314-318, 5p

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β 2 -Agonist (LABA) Combinations in COPD.

Autor: Sion KYJ; Real World Strategy and Analytics, Mapi Group, Houten, The Netherlands.; Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands., Huisman EL; Real World Strategy and Analytics, Mapi Group, Houten, The Netherlands.; Novo Nordisk, Alphen aan den Rijn, The Netherlands., Punekar YS; ViiV Healthcare, GlaxoSmithKline, Brentford, Hounslow, Middlesex, UK., Naya I; Respiratory Medicine Development Centre, GlaxoSmithKline, Brentford, Hounslow, Middlesex, UK., Ismaila AS; Value Evidence and Outcomes, GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC, 27709-3398, USA. afisi.s.ismaila@gsk.com.; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. afisi.s.ismaila@gsk.com.

Publikováno v: Pulmonary therapy [Pulm Ther] 2017 Dec; Vol. 3 (2), pp. 297-316. Date of Electronic Publication: 2017 Aug 22.